Ketamine enhances the expression of serine racemase and D-amino acid oxidase mRNAs in rat brain

被引：13

作者：

Takeyama, Kazuhide

Yoshikawa, Masanobu

Oka, Tetsuo

Kawaguchi, Mitsuru

Suzuki, Toshiyasu

Hashimoto, Atsushi ^{[1
]}

机构：

[1] Tokai Univ, Sch Med, Dept Pharmacol, Isehara, Kanagawa 2591143, Japan

[2] Tokai Univ, Sch Med, Dept Anesthesiol, Isehara, Kanagawa 2591143, Japan

[3] Tokyo Dent Coll, Dept Pharmacol, Mihama Ku, Chiba 2618502, Japan

来源：

EUROPEAN JOURNAL OF PHARMACOLOGY | 2006年 / 540卷 / 1-3期

关键词：

mu-amino acid oxidase; anesthetics; ketamine; NMDA receptor; schizophrenia; serine racemase;

D O I：

10.1016/j.ejphar.2006.04.021

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

We have evaluated the effects of the acute administration of noncompetitive N-methyl-D-aspartate receptor antagonist, ketantine, on the expression of serine racemase and D-amino acid oxidase mRNAsin several brain areas of rats. The ketamine administration produced a dose-dependent and transient elevation in the levels of serine racemase and D-amino acid oxidase mRNAs in all the brain areas. These findings suggest that there is a relationship between the gene expression of the D-serine-related enzymes and the blockade of the N-methyl-D-aspartate receptors. (c) 2006 Elsevier B.V All rights reserved.

引用

页码：82 / 86

页数：5

共 35 条

[1] Ketamine-induced changes in rat behaviour: A possible animal model of schizophrenia [J].

Becker, A ;

Peters, B ;

Schroeder, H ;

Mann, T ;

Huether, G ;

Grecksch, G .

PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY, 2003, 27 (04) :687-700

[2] Genetic and physiological data implicating the new human gene G72 and the gene for D-amino acid oxidase in schizophrenia [J].

Chumakov, I ;

Blumenfeld, M ;

Guerassimenko, O ;

Cavarec, L ;

Palicio, M ;

Abderrahim, H ;

Bougueleret, L ;

Barry, C ;

Tanaka, H ;

La Rosa, P ;

Puech, A ;

Tahri, N ;

Cohen-Akenine, A ;

Delabrosse, S ;

Lissarrague, S ;

Picard, FP ;

Maurice, K ;

Essioux, L ;

Millasseau, P ;

Grel, P ;

Debailleul, V ;

Simon, AM ;

Caterina, D ;

Dufaure, I ;

Malekzadeh, K ;

Belova, M ;

Luan, JJ ;

Bouillot, M ;

Sambucy, JL ;

Primas, G ;

Saumier, M ;

Boubkiri, N ;

Martin-Saumier, S ;

Nasroune, M ;

Peixoto, H ;

Delaye, A ;

Pinchot, V ;

Bastucci, M ;

Guillou, S ;

Chevillon, M ;

Sainz-Fuertes, R ;

Meguenni, S ;

Aurich-Costa, J ;

Cherif, D ;

Gimalac, A ;

Van Duijn, C ;

Gauvreau, D ;

Quelette, G ;

Fortier, I ;

Realson, J .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2002, 99 (21) :13675-13680

[3] D-SERINE ANTAGONIZED PHENCYCLIDINE-INDUCED AND MK-801-INDUCED STEREOTYPED BEHAVIOR AND ATAXIA [J].

CONTRERAS, PC .

NEUROPHARMACOLOGY, 1990, 29 (03) :291-293

[4] The NMDA receptor glycine modulatory site: a therapeutic target for improving cognition and reducing negative symptoms in schizophrenia [J].

Coyle, JT ;

Tsai, G .

PSYCHOPHARMACOLOGY, 2004, 174 (01) :32-38

[5] A GLUTAMATERGIC HYPOTHESIS OF SCHIZOPHRENIA - RATIONALE FOR PHARMACOTHERAPY WITH GLYCINE [J].

DEUTSCH, SI ;

MASTROPAOLO, J ;

SCHWARTZ, BL ;

ROSSE, RB ;

MORIHISA, JM .

CLINICAL NEUROPHARMACOLOGY, 1989, 12 (01) :1-13

[6] Clinical and sensorimotor gating effects of ketamine in normals [J].

Duncan, EJ ;

Madonick, SH ;

Parwani, A ;

Angrist, B ;

Rajan, R ;

Chakravorty, S ;

Efferen, TR ;

Szilagyi, S ;

Stephanides, M ;

Chappell, PB ;

Gonzenbach, S ;

Ko, GN ;

Rotrosen, JP .

NEUROPSYCHOPHARMACOLOGY, 2001, 25 (01) :72-83

[7]

Follesa P, 1996, J NEUROSCI, V16, P2172

[8]

FUKUI K, 1992, J BIOL CHEM, V267, P18631

[9] Schizophrenia genes, gene expression, and neuropathology: on the matter of their convergence [J].

Harrison, PJ ;

Weinberger, DR .

MOLECULAR PSYCHIATRY, 2005, 10 (01) :40-68

[10] Free D-aspartate and D-serine in the mammalian brain and periphery [J].

Hashimoto, A ;

Oka, T .

PROGRESS IN NEUROBIOLOGY, 1997, 52 (04) :325-353

← 1 2 3 4 →